Asia Pacific Biomarkers Market
Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Asia Pacific biomarkers market is projected to reach USD 26.40 billion by 2030 from USD 14.73 billion in 2025, at a CAGR of 12.4% from 2025 to 2030. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response; this market includes consumables, services, and software used for biomarker-related research.
KEY TAKEAWAYS
-
BY REGIONThe China biomarker market was the fastest growing segment with CAGR 14.7% in 2024.
-
BY OFFERINGBy offering, the consumables segment is the highest growing segment with CAGR 13.1 % in 2024
-
BY TYPEBy type, the safety biomarker segment dominates the Asia Pacific biomarkers market with a CAGR of 12.9%
-
BY RESEARCH AREABy research area, the genomics segment is expected to dominate the market during the forecast period.
-
COMPETITIVE LANDSCAPERoche, Thermo Fisher Scientific, and QIAGEN were identified as key players in the Asia Pacific biomarkers market, given their strong market share and extensive product portfolios.
-
COMPETITIVE LANDSCAPERhythm Biosciences, Eagle Bio, and Personalis Inc. have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
Growing precision-medicine initiatives and the routine use of biomarker-based tests in cardiology, oncology, and other complex disease areas are driving rapid growth in the Asia Pacific biomarkers market.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The Asian-Pacific biomarker market is undergoing significant transformation, with manufacturing, regulatory, and clinical trends increasingly focused on the needs of precision medicine and complex biologic therapies in the rapidly expanding field of biomarkers. There is strong demand for high-throughput assay kits, multiplex testing instruments, and single-sample multi-omics solutions that deliver rapid turnaround times and clinically meaningful data, even at high testing volumes across cancer, cardiovascular disease, and chronic neurological disease. There is also demand for validated, automation-friendly biomarker solutions that meet regional regulatory requirements.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rapid expansion of clinical trials
-
Strong growth of CRO and CDMO ecosystem
Level
-
Uneven regulatory and reimbursement frameworks
Level
-
Expansion of local manufacturing and localization strategies
Level
-
Shortage of skilled bioinformatics and molecular pathology talent
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rapid expansion of clinical trials
The Asia Pacific region is becoming a strategic hub for global clinical research. This surge in trial activity increases demand for robust biomarker assays, companion diagnostics, and multi-omics workflows that can support patient stratification, response monitoring, and adaptive study designs in large, diverse populations in the Asia Pacific.
Restraint: Uneven regulatory and reimbursement frameworks
Reimbursement and regulatory pathways for genomic and biomarker-based diagnostics vary widely across the Asia Pacific, with relatively mature systems in Japan and Australia, but fragmented or unclear coverage rules in many emerging markets, slowing the adoption of companion diagnostics and advanced assays.
Opportunity: Expansion of local manufacturing and localization strategies
Governments in major Asia Pacific markets are actively incentivizing local IVD and biomarker manufacturing through production-linked incentives, tax benefits, and fast-track tender preferences, prompting global and regional players to set up plants and technology-transfer partnerships.
Challenges : Shortage of skilled bioinformatics and molecular pathology talent
The rapid rollout of high-throughput sequencing, multiplex immunoassays, and multi-omics platforms in Asia Pacific is outpacing the supply of trained bioinformaticians, clinical laboratory scientists, and pathologists to validate, run, and interpret complex biomarker tests.
ASIA PACIFIC BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Integrated biomarker and central-lab services supporting global and APAC clinical trials, including genomics, immuno-oncology, flow cytometry, and bioanalytical testing, with sample logistics and data management coordinated across China and regional sites | Enables sponsors to run complex, multi-center biomarker-driven trials in the Asia Pacific with consistent assay performance, faster sample-to-result turnaround, and streamlined data packages that support regulatory submissions and companion-diagnostic development |
 |
Preclinical and translational biomarker discovery platforms using extensive PDX and syngeneic tumor models, in vitro assay services, and tissue-based biomarker analysis to help pharma and biotech companies in the Asia Pacific evaluate drug response and identify predictive biomarkers | Provides a seamless path from target discovery to clinical biomarker strategy by generating clinically relevant biomarker signatures, de-risking oncology pipelines, and accelerating the selection of assays that can be advanced into regulated clinical trials across the Asia Pacific |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Asia-Pacific biomarkers market is a tightly interconnected ecosystem of assay developers, kit and instrument suppliers, hospital and reference laboratories, and regional and multinational biopharma companies. Manufacturers deliver biomarker panels and platforms tailored to local populations, while pharma sponsors, CROs, and CDMOs integrate these into clinical trial design, patient segmentation, and therapeutic response monitoring. Hospitals and diagnostic networks embed validated biomarker solutions into routine care, supported by health-IT vendors, logistics providers, and distributors that help scale access across diverse APAC health systems.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Asia Pacific Biomarkers Market, By Offering
In 2024, consumables accounted for the largest share of the Asia-Pacific biomarkers market because assay kits, reagents, plates, and cartridges are frequently used in clinical testing and extensive research studies.
Asia Pacific Biomarkers Market, By Type
In 2024, safety biomarkers accounted for the highest share due to their increasing use in tracking toxicity and adverse drug reactions during clinical trials and post-marketing surveillance.
Asia Pacific Biomarkers Market, By Research Area
In?????? 2024, genomics held the major share by research area, due to the widespread use of gene panels and next-generation sequencing in cancer and rare disease research to find composite and actionable biomarker signatures.
Asia Pacific Biomarkers Market, By Technology
In 2024, immunoassay technologies accounted for the highest share because of their widespread use in hospital and reference laboratories, ease of use, and compatibility with automation.
Asia Pacific Biomarkers Market, By Disease Indication
In 2024, cancer had the highest share due to the high demand for molecular and protein biomarkers for early detection, therapy selection, minimal residual disease monitoring, and treatment response assessment.
Asia Pacific Biomarkers Market, By Application
Clinical diagnostics held the largest share of the Asia Pacific biomarkers market in 2024, driven by the growing need for biomarker-based assays for infectious diseases, cancer, and cardiovascular diseases in hospitals and reference labs.
Asia Pacific Biomarkers Market, By End user
Pharmaceutical and biotechnology companies were the highest-end user segment because biomarkers are essential for pipeline development, clinical trial optimization, and regulatory approval of companion diagnostics.
REGION
China to be fastest-growing country in market during forecast period
In 2024, the Asia Pacific emerged as the fastest-growing region in the global biomarkers market, led by countries such as China, India, South Korea, Australia, and Singapore, which are investing heavily in oncology-focused research networks, cancer centers, and innovation-driven hospitals. A rapidly expanding pipeline of oncology and autoimmune therapies, combined with national precision medicine initiatives and a rising number of biomarker-driven clinical trials, is driving strong demand for biomarker assays and companion diagnostics across genomics, proteomics, imaging, and immunoassay platforms in the Asia Pacific region.
ASIA PACIFIC BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
In the Asia Pacific biomarkers market, Roche (Star Player) came up with several assays, immunoassay analyzers, and point-of-care systems that labs trust for high-volume routine testing and cardiac, infectious, and metabolic panels. JSR Corporation (Emerging Leader) is an emerging player on the genomics side, building a strong position in translational oncology and genomics by offering NGS-based genomics services, biomarker discovery, and advanced bioinformatics rather than selling its own branded NGS instruments.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- QIAGEN (Germany)
- JSR Corporation (Japan)
- Merck KGaA (Germany)
- Abbott (US)
- WuXi AppTec (China)
- Agilent Technologies (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 13.51 Billion |
| Market Forecast in 2030 (Value) | USD 26.40 Billion |
| Growth Rate | CAGR of 12.4% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | China, Japan, India, South Korea, Australia, Rest of APAC |
WHAT IS IN IT FOR YOU: ASIA PACIFIC BIOMARKERS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Sustainability-aligned biomarker lab network strategy | Mapped how leading APAC hospitals and reference labs are redesigning biomarker workflows using consolidated test menus, reusable consumables, and integrated middleware to cut energy use, cold-chain dependence, and hazardous-waste generation across regional networks. | Helps vendors and service providers position biomarker offerings as low-carbon, resource-efficient solutions that support national sustainability targets and hospital accreditation requirements in Asia Pacific. |
| Deep dive on APAC biomarker platform adoption | Segmented end-user demand for immunoassay analyzers, NGS and multi-omics platforms, and decentralized testing solutions across tier-1 urban centers versus secondary cities, highlighting price-sensitivity, service expectations, and localization needs for each cluster. | Enables commercial teams to tailor portfolio mix, pricing, and service models to distinct APAC customer archetypes, improving win rates in tenders and accelerating uptake of advanced biomarker solutions. |
RECENT DEVELOPMENTS
- February 2024 : Abbott entered into a partnership with Fujirebio(Japan) to develop the research-use-only neurofilament-light chain (Nf-L) neurology biomarker assay.
- October 2024 : JSR Corporation (Crown Biosciences) joined the Eurostars-funded MY-SIGNATURE project, led by Novigenix with Radboud University Medical Centre, to develop MYELO-SCAN-a biomarker-based liquid biopsy test targeting MDSC infiltration in mCRPC. The test aims to improve patient stratification and address therapy resistance in prostate cancer treatment.
- November 2022 : Roche partnered with Redcliffe Labs(India) to offer the genetic testing of Alzheimer's using Elecsys ß-Amyloid (1-42) CSF II (cerebrospinal fluid), Elecsys Phospho-Tau (181P) CSF, and Elecsys Total-Tau CSF immunoassays.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global Asia Pacific Biomarkers Market . In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the Asia Pacific Biomarkers Market . The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Asia Pacific Biomarkers Market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Asia Pacific Biomarkers Market . These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the Asia Pacific Biomarkers Market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Top-down Approach
- After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The Asia Pacific Biomarkers Market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of biomarkers, including safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.
Stakeholders
- Academic & Research Institutes
- Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
- Contract Research Organizations (CROs)
- Biomarkers Service & Software Providers
- Diagnostics Companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Contract development and manufacturing organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global Asia Pacific Biomarkers Market based on offering, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Asia Pacific Biomarkers Market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the Asia Pacific Biomarkers Market
- To benchmark players in the Asia Pacific Biomarkers Market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Asia Pacific Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Asia Pacific Biomarkers Market